Login / Signup

Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain.

Antonio Olry de Labry LimaÓscar Díaz CastroJorge M Romero-RequenaM de Los Reyes García Díaz-GuerraVirginia Arroyo PinedaM Belén de la Hija DíazMeritxell AscanioJosep DarbàJosep M Cruzado
Published in: Clinical kidney journal (2021)
HK was usually managed by RAASi discontinuation and ion-exchange resin treatment. Most patients with HK were non-adherent to resins and those with severe HK remained with high potassium levels, despite bearing elevated healthcare expenditures.
Keyphrases
  • healthcare
  • high glucose
  • endothelial cells
  • health insurance
  • drug induced